Trial Profile
Comparison of Ticagrelor vs. Prasugrel on Inflammation, Arterial Stiffness, Endothelial Function, and Circulating Endothelial Progenitor Cells in Diabetic Patients With Non-ST Elevation Acute Coronary Syndrome (NSTE-ACS) Requiring Coronary Stenting
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 26 Apr 2019
Price :
$35
*
At a glance
- Drugs Ticagrelor (Primary) ; Prasugrel
- Indications Acute coronary syndromes
- Focus Therapeutic Use
- 01 Nov 2016 Status changed from active, no longer recruiting to completed according to results published in the Journal of the American College of Cardiology.
- 01 Nov 2016 Primary endpoint of changes in brachial artery flow mediated dilation has been met, according to results published in the Journal of the American College of Cardiology.
- 01 Nov 2016 Primary endpoint of changes in circulating number of endothelial progenitor cells has been met, according to results published in the Journal of the American College of Cardiology.